Candesartan 8mg

DRUG3 trials

Sponsors

Chong Kun Dang Pharmaceutical, Ottawa Hospital Research Institute

Conditions

Essential HypertensionHypertension

Phase 1

Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs

CompletedNCT02548286

Chong Kun Dang PharmaceuticalHypertension

Start: 2015-08-31End: 2015-09-30Updated: 2015-12-07

Phase 2

A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension

Chong Kun Dang PharmaceuticalEssential Hypertension

Start: 2014-03-31End: 2015-06-30Target: 456Updated: 2015-03-30

Phase 4

SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy

Not yet recruitingNCT07687160

Ottawa Hospital Research InstituteHypertension

Start: 2026-09-01End: 2028-02-01Target: 30Updated: 2026-07-13